Source comparison
MK-677 Oral vs Injectable: Research Application Comparison
The table below compares practical and pharmacological dimensions of MK-677 oral vs injectable formulations for research use. Bioavailability 60–70% with first-pass metabolism ~100% (bypasses first-pass) Oral achieves equivalent systemic exposure with dose adj
This comparison does not assign a generated winner or score.
- The table below compares practical and pharmacological dimensions of MK-677 oral vs injectable formulations for research use.
- Bioavailability
- 60–70% with first-pass metabolism
- ~100% (bypasses first-pass)
- Oral achieves equivalent systemic exposure with dose adjustment
- Tmax (Time to Peak Plasma)
- 2–3 hours post-dose
- 30–90 minutes post-injection
- Injectable offers faster onset; oral provides more sustained elevation
- Storage Requirements
- Room temperature (15–25°C), 12–24 months shelf life
- Refrigeration at 2–8°C required post-reconstitution; 28-day use window
- Oral eliminates cold-chain logistics and temperature excursion risk
- Reconstitution
- None. Arrives ready to dose
- Requires bacteriostatic water, sterile technique, and careful mixing
- Every reconstitution introduces contamination risk and user error
- Participant Training
- None (take with water)
- Injection technique, site rotation, sharps disposal required
- Oral protocol reduces onboarding time and liability
- Compliance in 12+ Week Protocols
- High (>90% adherence typical)
- Moderate (injection fatigue increases dropout 15–25%)
- Oral sustains adherence across extended study durations
- Adverse Events
- GI discomfort in 10–15% (transient)
- Injection site reactions in 10–20%; same systemic GI effects
- Both formulations share core GH-related side effects; injectable adds local reactions